A Phase 3 interventional study of Mexiletine granules for prolonged-release oral suspension in Myotonic Dystrophy, sponsored by Lupin Ltd.. Enrolling by invitation at 6 sites in 6 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by Lupin Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Myotonic Dystrophy with a site in Belgium — 8 open to participants now, 9 under way, 4 of them phase 3. Myotonic Dystrophy · Belgium.
Among the 10 studies in Myotonic Dystrophy with a site in Belgium, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2025, is one of 4 in phase 3, and was the 6th registered.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →8 of the 10 studies in Myotonic Dystrophy with a site in Belgium are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Belgium, Australia, Canada and 7 more countries
Ages 7–16 · Men only
Dyne Therapeutics · Sites in Belgium, United States, Australia and 9 more countries
Ages 16+
Lupin Ltd. · Sites in Belgium, Denmark, Germany and 3 more countries
Ages 16+
Centre Hospitalier Universitaire de Liege · Sites in Belgium
Ages 18+
Centre Hospitalier Universitaire de Liege · Sites in Belgium, Czechia, Egypt and 4 more countries
Ages 1–80 · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 4
First in 2020; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 176 is above the median of 40 across 68 interventional studies indexed under Myotonic Dystrophy.
Median enrollment 114 across the 10 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 7 most frequent:
Lupin Ltd. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.
Lupin Ltd. has 6 studies filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
3 of the studies in Myotonic Dystrophy with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06523400Phase 3Lupin Ltd.The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 | 2027-06 |
| NCT06138743Sarepta Therapeutics, Inc.Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Myotonic Dystrophy with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label extension study intended to evaluate the long-term safety and efficacy of mexiletine PR in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the parent study MEX-DM-302.
At the completion of the final visit in Study MEX-DM-302 patients who continued to meet the eligibility criteria will be invited to rollover into this open-label study for an additional 18 months. All patients who elect to continue into this open-label study will receive active mexiletine (no placebo).
Mexiletine PR will be started as 167 mg once a day (QD) treatment regimen. The dose will be titrated up at Week 1 to 333 mg and at Week 2 to a maximum dose of 500 mg QD depending on tolerability. If unable to tolerate the escalated dose, the dose will be reduced by one dose step during the titration period of the study to a maximum tolerated dose. Study drug should be taken with food at approximately the same time of the day every day, preferably in the morning (See Section 7 for further details on reconstitution and dosing titration).
Safety assessments include patient- and physician-reported adverse events, standard clinical laboratory evaluations, physical examinations, and vital signs. In addition, ECG, Holter monitors, and echocardiogram assessments will be collected to assess cardiac safety during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any cardiac safety associated condition including any of the following criteria detected by cardiac evaluations including 24-hr Holter monitor, echocardiogram and clinical evaluations:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mexiletine PR 167 mg (mexiletine HCl 200 mg) Mexiletine PR 333 mg (mexiletine HCl 400 mg) OR Mexiletine PR 500 mg (mexiletine HCl 600 mg)
Drug: Mexiletine granules for prolonged-release oral suspension
Mexiletine PR
To assess the long-term efficacy of once daily mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed MEX-DM-302 study.
Handgrip relaxation time in DM1 patients by mean change in baseline of handgrip relaxation time (seconds) after maximal voluntary isometric contraction (MVIC)
Time frame: 78 weeks
To assess the long-term safety of once daily mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the MEX-DM-302 study
Number and frequency of AEs/SAEs throughout the study while on treatment
Time frame: 78 weeks
Mean change in VAS
Score for muscle stiffness (myotonia severity) as self-reported by patients on a Visual Analog Scale (VAS)
Time frame: 78 weeks
Mean change in MBS scores
Mean change in Myotonia Behavior Scale (MBS) scores on a scale of 0 (no stiffness) to 5 (incapacitating stiffness)
Time frame: 78 weeks
Mean change in health-related quality of life
Mean change in health-related quality of life (measured by INQoL)
Time frame: 78 weeks
Mean change in DM1-Activ-c scale (DM1 patients only)
Mean change in measure of activity and social participation (measured by a Rasch-built scale with a 0-100 interval range)
Time frame: 78 weeks
Mean change in time to perform the 10-meter Walk Test
Mean change in time (seconds) to perform the 10-meter Walk Test (10mWT)
Time frame: 78 weeks
Mean change in handgrip relaxation time
Mean change in maximal voluntary isometric contraction (MVIC) and relaxation time by Video-recording of Hand Opening Time (VHOT) functional evaluation
Time frame: 78 weeks
Mean change in time to perform Timed-up and go (TUG) test
Mean change in time (seconds) to perform Timed-up and go (TUG) test
Time frame: 78 weeks
Mean change in health-related quality of life measured by EQ-5D
Mean change in health-related quality of life measured by EQ-5D (5-point scale)
Time frame: 78 weeks
Mean change in Myotonic Dystrophy Health Index (MDHI) score (DM1 patients)
Mean change in Myotonic Dystrophy Health Index (MDHI) score (DM1 patients) as measured by patient's perceived health
Time frame: 78 weeks
Mean change in Myotonic Dystrophy 2 Health Index (MD2HI) score (DM2 patients)
Mean change in Myotonic Dystrophy 2 Health Index (MDHI) score (DM2 patients) as measured by patient's perceived health
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by changes in ECG
Mean change in ECG (PR, QRS, and QTc intervals in units of milliseconds \[ms\]) from baseline
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by changes in ECG (HR)
Mean change in ECG (HR in units of beats per minute) from baseline
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by AEs
Incidence of treatment emergent adverse events (TEAEs), treatment-related TEAEs, serious AEs, and patient discontinuation rate
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (hematology measured in units of μL [microliters]) from change in baseline
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by hematology parameters in units of μL: white blood cell (WBC) with differential (absolute count), red blood cells (RBC), platelet count, and red blood cell indicies.
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (hematology measured in units of % [percentage]) from change in baseline
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by hematology parameters in units of %: white blood cell (WBC) and differential (percentage) and hematocrit.
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (hematology measured in g/dL [units of grams per deciliter]) from change in baseline
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by hematology parameters in units of g/dL: hemoglobin.
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of mmol/L) from change in baseline
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by chemistry parameters in units of mmol/L: chloride, carbon dioxide, potassium, and sodium
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of U/L) from change in baseline
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by chemistry parameters in units of U/L: alkaline phosphatase, aspartate aminotransferase (AST), aspartate transaminase (ALT), gamma-glutamyl transferase (GGT), and creatine phosphokinase.
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of g/dL) from change in baseline
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by chemistry parameters in units of g/dL: albumin and total protein.
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of mg/dL) from change in baseline
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by chemistry parameters in units of mg/dL: blood urea nitrogen (BUN), calcium, creatinine (eGFR), glucose, total bilirubin, and magnesium.
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (urinalysis) from change in baseline
Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations as measured by urinalysis parameters (measured as normal or abnormal): appearance, specific gravity, pH, protein, glucose, ketones, blood, leukocyte esterase, nitrite, bilirubin, urobilinogen, and microscopic examination.
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by vital signs (pulse)
Assess the long-term safety of mexiletine PR by vital signs (pulse in units of bpm \[beats per minute\]) from change in baseline
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by vital signs (body temperature)
Assess the long-term safety of mexiletine PR by vital signs (body temperature in units of Fahrenheit or Celsius) from change in baseline
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by vital signs (blood pressure)
Assess the long-term safety of mexiletine PR by vital signs (blood pressure \[diastolic and systolic\] in units of mmHg \[millimeters of mercury\]) from change in baseline
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by vital signs (respiration)
Assess the long-term safety of mexiletine PR by vital signs (respiration in units of breaths per minute) from change in baseline
Time frame: 78 weeks
Assess the long-term safety of mexiletine PR by physical examinations
Assess the long-term safety of mexiletine PR by change in baseline from physical examinations (normal or abnormal) in the following regions and systems: general appearance, head and neck, heart, lung, abdomen, chest and back, upper extremities, lower extremities, neurological, and dermatological.
Time frame: 78 weeks
Started Sep 2025 (actual). Primary completion is estimated for May 2028, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupin Ltd.